olaparib
astrazeneca,merck
['solo1', 'olaparib', 'brca', 'ovarian']
presented at #esmo22, new long-term outcome possibilities in adv ovarian cancer - the solo1/gog-3004 phase iii trial found 2 years of maintenance olaparib brought significant 7-yr os in new diagnosis aoc + brca mutation - more breaking data updates to come from #noeticinsight! 